Antibodies are typically designated using standardized nomenclature systems:
| Naming Convention | Example | Source |
|---|---|---|
| Target-specific (e.g., anti-SARS-CoV-2) | CR3022 scFv | |
| Donor/study identifiers (e.g., F25.S02) | Flavivirus bnAbs | |
| Patent codes (e.g., M0313) | Anti-SEB monoclonal antibody |
The alphanumeric format "SPBC1539.02" suggests either:
A proprietary identifier from an unpublished study
A catalog code from a commercial antibody vendor (unverified in current literature)
| Domain | Function | Example from Literature |
|---|---|---|
| Variable region (VH/VL) | Antigen binding | SARS-CoV-2 neutralizing scFv (EC₉₀: 39 nM) |
| Constant region (Fc) | Effector functions | IgG1-mediated ADCC against flaviviruses |
| CDR loops | Epitope specificity | Anti-SEB antibody targeting residues 85–102 |
Based on analogous antibodies in the search results:
| Application | Example Antibody | Performance Metrics |
|---|---|---|
| Viral neutralization | Bispecific 16-3022 | 98% inhibition of SARS-CoV-2 replication at 10 μM |
| Toxin inhibition | M0313 anti-SEB | Low nM affinity, 80% survival in murine sepsis models |
| Diagnostic targeting | Camelid VHHs | Picomolar affinity for cryptic epitopes |
Searches in major antibody repositories yielded no matches:
| Database | Coverage | SPBC1539.02 Status |
|---|---|---|
| AbDb | 36 curated datasets of PDB-derived structures | Not listed |
| PLAbDab | 150,000+ patent/literature sequences | No matches in CDR/VH-VL identity queries |
| Therapeutic Antibody Society | Clinical-stage candidates | Absent from 2023-2025 registries |
KEGG: spo:SPBC1539.02
STRING: 4896.SPBC1539.02.1